Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L.
Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Olema Oncology is a biopharmaceutical company focused on innovating medicines for breast cancer and beyond. The company is in a growth stage where it is actively pursuing better treatments to help patients feel better and improve their quality of life. With a pipeline of promising candidates like palazestrant, Olema Oncology is expanding its presence in the oncology market and striving to make a significant impact in the treatment of breast cancer and related diseases.
Olema Oncology has achieved significant milestones in its journey towards developing effective treatments for breast cancer. The lead candidate, palazestrant (OP-1250), shows best-in-class potential for metastatic breast cancer. The company is conducting clinical trials such as the OPERA-01 Phase 3 study targeting patients with advanced and/or metastatic ER+/HER2- breast cancer. These milestones highlight Olema Oncology's commitment to advancing innovative therapies and improving patient outcomes in the oncology field.
Olema Oncology's involvement in advancing palazestrant for breast cancer and conducting the OPERA-01 Phase 3 study exemplifies the company's dedication to improving treatment options for patients. These case studies demonstrate the impact of Olema Oncology's innovative approach to developing oral medicines with best-in-class potential for metastatic breast cancer. By focusing on patient-centric research and clinical trials, the company aims to address the complex journey that patients and caregivers face in managing breast cancer.
Key events in Olema Oncology's recent history include presenting compelling preclinical data on OP-3136 and palazestrant combinations, participating in the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer, and reporting inducement grants under Nasdaq Listing Rule 5635(c)(4). These events highlight the company's strategic direction, commitment to advancing oncology research, and recognition within the industry for its innovative approaches to developing treatments for breast cancer and related diseases.
-
Active
Health Care/Life Sciences
780 Brannan Street San Francisco California 94103 United States...
United States
74
Cyrus L. Harmon (Director)
Shane William Charles Kovacs (Chief Operating & Financial Officer)
Mark Shilkrut (Vice President-Clinical Development)
-
$11.55
Achieving business success in today’s competitive landscape requires specialized expertise, seamless operations, and continuous innovation. Establishing a Virtual Delivery Center (VDC) can transform your company’s growth journey by ensuring efficiency, scalability, and long-term value.
Why Choose a VDC for Your Company?
1. Cost Optimization:
Save up to 70% on operational costs by leveraging remote teams and streamlined processes.
2. Expert Access:
Gain instant access to highly skilled professionals, ensuring faster and smoother project execution.
3. Scalable Teams:
Scale your team as business needs evolve, from initial project setup to long-term support.
4. Accelerated Timelines:
Leverage 24/7 global teams to reduce project delays and speed up implementation.
5. Continuous Support:
Ensure uninterrupted business performance with ongoing maintenance and updates.
Unlock Business Success with a VDC By establishing a VDC, your company can overcome operational challenges, achieve seamless system integration, and maximize ROI. Stay ahead in today’s dynamic market with a future-ready business strategy powered by a Virtual Delivery Center. Learn More About Us
Book A Meeting To Setup Your VDCAiDOOS Information Wiki provides comprehensive information about products, companies, and individuals.
-
Health Care/Life Sciences
780 Brannan Street San Francisco California 94103 United States...
United States
74+
-
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L.
Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Achieving business success in today’s competitive landscape requires specialized expertise, seamless operations, and continuous innovation. Establishing a Virtual Delivery Center (VDC) can transform your company’s growth journey by ensuring efficiency, scalability, and long-term value.
Why Choose a VDC for Your Company?
1. Cost Optimization:
Save up to 70% on operational costs by leveraging remote teams and streamlined processes.
2. Expert Access:
Gain instant access to highly skilled professionals, ensuring faster and smoother project execution.
3. Scalable Teams:
Scale your team as business needs evolve, from initial project setup to long-term support.
4. Accelerated Timelines:
Leverage 24/7 global teams to reduce project delays and speed up implementation.
5. Continuous Support:
Ensure uninterrupted business performance with ongoing maintenance and updates.
Unlock Business Success with a VDC By establishing a VDC, your company can overcome operational challenges, achieve seamless system integration, and maximize ROI. Stay ahead in today’s dynamic market with a future-ready business strategy powered by a Virtual Delivery Center. Learn More About Us
Book A Meeting To Setup Your VDC